TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02178085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flow imaging
Description: Participants will undergo morphological and then flow MRI. Flow MR images will be processed adequately to obtain quantitative values of arterial and venous flow as well as CSF flow.
Study: NCT02737397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMI-001 (SJP-304 and SJP-223)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SJP-304

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SJP-223

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Study: NCT03636087

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Working Length Determination
Description: The length of the root canal will be measured using periodical radiographs and Electronic Apex Locators (As a part of conventional root canal treatment established protocol)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Working Length Determination
Description: The length of the root canal will be measured using periodical radiographs and Electronic Apex Locators (As a part of conventional root canal treatment established protocol)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root canal instrumentation and chemo-mechanical preparation
Description: Rotary files used to properly instrument and prepare canals length and size (As a part of conventional root canal treatment established protocol)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root canal instrumentation and chemo-mechanical preparation
Description: Rotary files used to properly instrument and prepare canals length and size (As a part of conventional root canal treatment established protocol)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root canal obturation
Description: Gutta Percha filling materials will be used to fill the root canal space with root canal sealer (As a part of conventional root canal treatment established protocol)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root canal obturation
Description: Gutta Percha filling materials will be used to fill the root canal space with root canal sealer (As a part of conventional root canal treatment established protocol)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronal restoration build up
Description: A Build up material to seal the accessed tooth properly (As a part of conventional root canal treatment established protocol)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronal restoration build up
Description: A Build up material to seal the accessed tooth properly (As a part of conventional root canal treatment established protocol)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Changing gloves before obturation
Description: The treating dentist will change gloves before obturation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Disinfecting rubber dam
Description: 2.25% Sodium Hypochlorite solution will be used to disinfect the rubber dam surface
Study: NCT02737397

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01984411

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radial Technical
Description: Vascular Access for cardiac catheterization
Study: NCT03267849

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wearing swimming goggles or having laser suturelysis
Description: Two images will be compared in each subject at two different eye pressures with the higher pressure having been produced by the interventions
Study: NCT01984411

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Technical
Description: Vascular Access for cardiac catheterization
Study: NCT03636087

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The use of new instruments at time of obturation
Description: A new instrument's kit will be use at the time of obturation
Study: NCT01984411

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omnipaque

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omnipaque
Study: NCT03636087

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Cone Beam Computed Tomography scanning (CBCT)
Description: CBCT will be taken before treatment and one year after completion
Study: NCT06750445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Patients in the fluoxetine group received oral fluoxetine starting at 40 mg/day for six months. Treatment was discontinued if serious adverse reactions developed or if no improvement was observed after dose escalation. Compliance and treatment progress were monitored via telephone follow-ups. For patients unable to have a bowel movement for three consecutive days or experiencing intolerable symptoms, polyethylene glycol (PEG, 10 g) was provided as rescue medication. Bowel movements within 24 hours of rescue medication use were excluded from the count of complete spontaneous bowel movements (CSBM).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol 400 0.4%
Description: The control group (PEG) used polyethylene glycol as a rescue medication under the same conditions, following similar monitoring and follow-up procedures.
Study: NCT01457573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Alpha blocker used to in the treatment of urinary difficulties related to enlarged prostate or symptomatic benign prostatic hypertrophy. All men will receive Tamsulosin (Flomax®) 0.4 mg, 1 tab, per morning with Solifenacin (Vesicare®).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: Antispasmodic/anticholinergic used to treat overactive bladder. All men will receive Solifenacin (Vesicare®) 5 mg, 1 tab, per morning with Tamsulosin.
Study: NCT05905900

Intervention type: COMBINATION_PRODUCT
Intervention: Emergent IV Dye Preparation
Description: Diphenhydramine 50 mg IV once, famotidine 20 mg IV once, and dexamethasone 10 mg IV once
Study: NCT03599388

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self- management for adequate sleep intervention (SASI)
Description: Bedtimes and wake times will be prescribed each week for each participant and allow for gradual increases in sleep opportunity. Bedtimes will be set 15 minutes earlier each week provided sleep efficiency remains \>90%. Earlier betimes will extend sleep duration by increasing the opportunity for sleep. Wake times will not be changed because wake times are often determined by external demands, such as work schedules
Study: NCT03636087

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cone Beam Computed Tomography scanning (CBCT)
Description: CBCT will be taken before treatment and one year after completion

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiographic imaging using periapical radiographs
Description: Periapical radiographs will be taken before, during and one year after the treatment completion (As a part of conventional root canal treatment established protocol)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiographic imaging using periapical radiographs
Description: Periapical radiographs will be taken before, during and one year after the treatment completion (As a part of conventional root canal treatment established protocol)
Study: NCT02508259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suramin
Description: 20 mg/kg IV in 50 ml saline over 30 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 50 ml IV over 30 minutes
Study: NCT01780376

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: whole-body vibration (WBV)
Description: whole-body vibration (4 mm amplitude, 25,30,35,40,45,50 Hz)
Study: NCT01260337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Portion controlled diet
Description: Participants learn skills for changing nutritional and lifestyle habits and diabetes management follow a program that includes eating a pre-packaged, portion controlled meal for weight loss in addition to attending the behavior modification groups

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Support and Education
Description: The DSE groups will consist of educational sessions offered for diabetes support and education which will include sessions on diet/nutrition, exercise, foot care and living with diabetes.
Study: NCT03431064

Intervention type: OTHER
Intervention: Lung Recruitment Maneuver
Description: Lung Recruitment Maneuver by Anesthesiologist

Intervention type: OTHER
Intervention: Fluid Administration
Description: Administration of IV Fluid by Anesthesiologist
Study: NCT03739216

Intervention type: DEVICE
Intervention: ClariFix
Description: The ClariFix device is a handheld cryosurgical device which provides focal, controlled freezing to the target tissue.
Study: NCT01873781

Intervention type: DRUG
Intervention: Cyclopentolatehydrochloride
Description: Cyclopentolatehydrochloride 0.5% (Thilo, Alcon, Vienna), dose: 1 drop for study eye
Study: NCT00851409

Intervention type: DRUG
Group type: OTHER
Intervention: Recombinant Human C1 Inhibitor
Description: 50 IU/kg rhC1INH, IV injection over 4 to 5 minutes, once weekly over an 8-week treatment period.
Study: NCT01876368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of LCZ696

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of Olmesartan
Study: NCT03901157

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yogurt A: Active
Description: Free fat yogurt containing oil-filled alginate gels

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Yogurt B: Control
Description: Free fat yogurt containing the same amount of fat as the active one, and empty alginate gels
Study: NCT02812654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 75mg/m2 (cycle 1,2 and 3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide 9 g/m2 (cycle 1 and 3)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: radiotherapy: 25 Gy / 5 x 500 cGy/day
Study: NCT04458467

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Infusion
Description: A continuous infusion of ropivacaine 0.2% (6 mL/hr, 4 mL patient controlled bolus with 30-minute lockout) will be initiated in the recovery room.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated Intermittent Boluses
Description: Administration of automated intermittent boluses of ropivacaine 0.2% (8 mL every 2 hr with 4 mL patient controlled bolus with 30-minute lockout) will be initiated in the recovery room, but with a 5-hour delay for the first bolus (can be overridden by patients if they would like to initiate their perineural infusion earlier than 5 hours).
Study: NCT00647361

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurally adjusted ventilatory assist (NAVA) provided by a commercially available mechanical ventilator (Servo i, Maquet Critical Care, Solna, Sweden).
Description: Neurally adjusted ventilatory assist (NAVA) and pressure support ventilation (PSV)
Study: NCT04213482

Intervention type: RADIATION
Intervention: Panoramic Radiography
Description: Diagnostic Panoramic Dental Radiographs were taken.

Intervention type: RADIATION
Intervention: Panoramic Radiography
Description: Diagnostic Panoramic Dental Radiographs were taken.
Study: NCT02917733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3039478
Description: Administered orally
Study: NCT01570296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib and BKM120
Description: Dose escalation study of gefitinib and BKM120 with expansion cohort
Study: NCT03930758

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Behavior intervention of uphill exercise
Description: 40 minutes of uphill exercise

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dietary intervention of exercise before the meal
Description: 40 minutes of uphill exercise completed 1 h before the meal

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dietary intervention of uphill exercise
Description: 40 minutes of uphill exercise

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dietary intervention of exercise after the meal
Description: 40 minutes of uphill exercise started 1 hour after gthe meal

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Behavior intervention of downhill exercise
Description: 40 minutes of downhill exercise

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dietary intervention of exercise before the meal
Description: 40 minutes of downhill exercise completed 1 hour before the meal
Study: NCT03761550

Intervention type: COMBINATION_PRODUCT
Intervention: pMDT(Process Implementation)
Description: The pMDT(Baseline Investigation) takes multi-model analgesia as the main technical means. Multimodal perioperative analgesia refers to the combination of analgesics, adjuvant drugs and analgesic techniques with different effects throughout the perioperative period to achieve the best curative effect of reducing postoperative acute and chronic pain.
Study: NCT03564626

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health-IT +/- Scheduled Follow Up
Description: * Training patient and caregiver on Patient Buddy and EncephalApp~* Counseling regarding readmission~* Daily contact through app~* Standard of care counseling regarding readmission and discharge instructions~* Follow up phone calls at Week 1 and Week 3~* In-person follow up visits at Week 2 and Week 4
Study: NCT03930758

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Behavioral intervention of downhill exercise
Description: 40 minutes of downhill exercise

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dietary intervention of exercise after the meal
Description: 40 minutes of downhill exercise started 1 hour after the meal

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Behavioral intervention of sedentary no-exercise trial
Description: Sedentary no-exercise trial

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Dietary intervention of eating two meals
Description: Meals eaten at 10 and 17 h during a sedentary trial
Study: NCT00779740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate
Description: The dose will be 50 mcg as MF in one spray (100 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mometasone furoate
Description: The dose will be 50 mcg as MF in one spray (50 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.
Study: NCT03062982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: 2 doses separated by 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: 2 doses separated by 7 days.
Study: NCT02432482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile Positively Smoke Free (mPSF)
Description: mPSF is a targeted, intensive behavioral cessation intervention designed for HIV-infected smokers. It is guided by the Social Cognitive Theory model. It includes 8 weekly sessions of audio/video messages to users, daily text messages, and a variety of other smartphone capabilities, e.g. play-a-tune, play-a-game, phone-a-friend, call the quitline.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Brief advice to quit (\<5 minutes) Self-help brochure Offer of nicotine patches
Study: NCT03488732

Intervention type: DEVICE
Intervention: Transcatheter valvular repair or replacement
Description: Transcatheter valvular repair (predominantly MitraClip for mitral regurgitation) or replacement (predominantly transcatheter aortic valve implantation for aortic stenosis)
Study: NCT01477593

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: circumcision with Shenghuan in Yan's method
Description: The foreskin is first separated from the glans.Then the inner ring is placed between them and over the glans. After adjusting the position of inner ring to retain 0.5cm inner foreskin, the operator install the outer ring over the foreskin and combine them together. Removal of excess foreskin is then performed upon the device.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: circumcision with Shenghuan in Peng's method
Description: The foreskin is first separated from the glans. Then the inner ring is placed on the outer layer of foreskin. Next, the rim of the foreskin is clamped with blood vessel forceps at the 3, 6, 9 and 12 o'clock points. An urologist and an assistant each hold two clamps to widen the opening of the foreskin, and pull it over the inner ring. After the inner and outer layers of the foreskin and the frenulum are symmetrically positioned, the assistant install the outer ring over the foreskin and gently combine it together. Removal of excess foreskin is then performed below the device.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional method with incision
Description: The procedure of conventional circumcision involve transection of the excess foreskin with reservation of 0.5cm inner foreskin, haemostasis by electrocautery and suture of skin edges with 4-0 absorption sutures.
Study: NCT02693119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elamipretide (MTP-131) 1% topical ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elamipretide (MTP-131) 1% topical ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elamipretide (MTP-131) 1% topical ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elamipretide (MTP-131) 1% topical ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle topical ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle topical ophthalmic solution
Study: NCT03738033

Intervention type: OTHER
Intervention: educational platform
Description: The platform would be opened before they entered the study.
Study: NCT00810472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HLA Matching
Description: HLA matching is exerted by selecting the donor with least-most additional HLA alleles. We will predict the waiting time for such a donor in order to assess eligibility for the trial \[8\]. In addition, we will dynamically adopt the degree of matching that is aimed at depending on the predicted time interval and actual waiting time: the first donors not exerting more than 7 mismatches at the triplet-amino-acid-residue-level (HLAMatchmaker method \[6\]) is accepted if the patient is waiting less than half of his predicted waiting time. The next available donor exerting a 2/6 match (or better) is assigned thereafter. The next graft will be assigned, regardless of HLA matching after 6 months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Penetrating keratoplasty
Description: Corneal transplantation.
Study: NCT04156750

Intervention type: DRUG
Group type: OTHER
Intervention: Iohexol
Description: Administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: Administered IV.
Study: NCT00810472

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Penetrating keratoplasty
Description: Corneal transplantation.
Study: NCT03039192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Intranasal esketamine solution 84 milligram (mg)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal Placebo solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: The standard of care antidepressant treatment (antidepressant monotherapy or antidepressant plus augmentation therapy) will be determined by the treating physician(s) based on clinical judgement and practice guidelines prior to randomization, and the treatment will be initiated on Day 1.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: The standard of care antidepressant treatment (antidepressant monotherapy or antidepressant plus augmentation therapy) will be determined by the treating physician(s) based on clinical judgement and practice guidelines prior to randomization, and the treatment will be initiated on Day 1.
Study: NCT04037046

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening HCV attached onto CCR screening
Description: Patients assigned to this strategy will receive an invitation letter for HCV screening with DBS and CCR screening with FOT at the primary care center to be performed by the general practitioner

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening HCV attached onto CCR screening by self-testing
Description: Patients assigned to this strategy will receive an invitation letter for self-testing for HCV screening with DBS, and CCR screening with FOT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening HCV at primary care center
Description: DBS for HCV screening at primary care center
Study: NCT00406354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Dosage form for the atomoxetine fast and slow titration arms consists of 2.5 mg, 10 mg, 20 mg, 25 mg, and 40 mg capsules. Double-blind treatment will consist of 3 capsules taken once per day for approximately 9 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Dosage form for the atomoxetine fast and slow titration arms consists of 2.5 mg, 10 mg, 20 mg, 25 mg, and 40 mg capsules. Double-blind treatment will consist of 3 capsules taken once per day for approximately 9 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double-blind treatment will consist of 3 matching placebo capsules taken once per day by mouth for approximately 9 weeks.
Study: NCT00387361

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Description: 20 minute post-operative osteopathic manipulation as described in the protocol